Polypharmacy: the silent cost driver in personal injury

How medication overload escalates costs and impairs recovery in insurance claims

Published 3 April 2026

Introduction

Polypharmacy, defined as concurrent use of five or more medications, has become increasingly common in insurance claim populations. Paradoxically, claimants on polypharmacy regimens often have worse functional outcomes, longer claim duration, and higher total medication costs than comparably injured claimants on simpler medication regimens.

Polypharmacy in insurance claims is not merely a medication management problem; it is a cost driver and outcome impedor. Each additional medication increases: direct medication cost, monitoring and consultation costs, adverse event risk, drug interaction risk, medication adherence complexity, and cognitive/physical impairment affecting rehabilitation participation and return-to-work achievement.

Definition and Prevalence in Insurance Claims

Defining Polypharmacy Thresholds

Standard healthcare definition of polypharmacy is five or more concurrent medications. However, in workers compensation and personal injury contexts, medication burden becomes clinically and financially significant at lower thresholds. Research suggests three or more chronic medications (excluding as-needed agents) creates meaningful interaction and side effect risk. Four or more medications represents substantial polypharmacy burden in injury-related claims.

Prevalence in Insurance Populations

Workers compensation claimants with significant injury typically have polypharmacy rates of 30 to 40 percent (five or more medications). In CTP claims with persistent injury symptoms beyond 12 months, polypharmacy prevalence increases to 40 to 50 percent. NDIS scheme participants with injury-related conditions frequently exceed five to seven concurrent medications.

Notably, polypharmacy prevalence is dramatically higher in insurance claim populations compared to age-matched general population, suggesting polypharmacy in injury claims is often medication-driven rather than disease-driven.

Cost Components of Polypharmacy

Direct Medication Costs

Average cost per chronic medication in Australia ranges from AUD 10 to 80 monthly depending on agent, PBS subsidisation, and private vs. co-payment structure. A claimant on five medications averages AUD 150-250 monthly. A claimant on ten medications averages AUD 300-500 monthly. Over a three-year claim: five medications cost AUD 5,400-9,000; ten medications cost AUD 10,800-18,000.

Cost escalation is non-linear: as polypharmacy increases, average cost per medication often increases due to addition of more expensive agents (opioids, specialty psychiatric medications, biological agents). A claimant transitioning from 5 to 10 medications may see cost increase of 200 to 250 percent, not 100 percent.

Monitoring and Consultation Costs

Polypharmacy requires increased clinical monitoring. A claimant on five medications typically requires quarterly GP consultations (AUD 200-300 per visit) and semi-annual specialist consultations if applicable (AUD 250-500 per visit). Annual monitoring cost: AUD 1,200-2,400. A claimant on ten medications requires monthly consultations and more frequent pathology monitoring: annual cost AUD 2,400-4,000.

Adverse Event and Complication Costs

Polypharmacy dramatically increases adverse event risk. Drug interaction risk increases exponentially with medication count: five medications have approximately 10 potential interactions; ten medications have approximately 45 potential interactions. Approximately 15 to 20 percent of medication-related adverse events in polypharmacy patients result in hospitalisation or emergency department presentation: AUD 3,000-8,000 per event.

Over a three-year claim period, a claimant on polypharmacy regimen has estimated 15 to 25 percent probability of medication-related adverse event requiring additional intervention. Expected cost: AUD 500-2,000 per claimant per year related to adverse event management.

Functional Impact of Polypharmacy

Cognitive Impairment and Fall Risk

Polypharmacy, particularly with psychoactive medications (sedatives, antidepressants, opioids), increases risk of cognitive impairment, dizziness, and falls. Studies indicate that claimants on polypharmacy regimens have 2-3 fold increased fall risk compared to age-matched non-polypharmacy controls. Falls create secondary injuries (fractures, head trauma) extending claim duration and increasing hospitalization costs.

Medication Non-Adherence

Claimants on complex polypharmacy regimens (five or more medications with varying dosing schedules) experience higher non-adherence rates. Approximately 40 to 50 percent of claimants on polypharmacy regimens take medications inconsistently or incorrectly. Non-adherence reduces therapeutic benefit, may necessitate dose escalation, and creates unpredictable symptom control.

Return-to-Work Impedance

Polypharmacy impairs return-to-work achievement. Cognitive and psychomotor effects limit job performance; side effects (sedation, nausea, dizziness) create functional limitations; medication-related falls or complications create secondary injury barriers to work resumption. Research indicates claimants on polypharmacy regimens have return-to-work rates approximately 20 to 40 percent lower than comparably injured claimants on simpler regimens.

Common Polypharmacy Patterns in Insurance Claims

The Pain-Psyche-Sleep Triad

Injury-related pain prompts opioid prescription. Opioids cause anxiety and insomnia. Anxiety prompts benzodiazepine or antidepressant prescription. Insomnia prompts hypnotic prescription. Final regimen: opioid, benzodiazepine, antidepressant, hypnotic, plus adjunctive medications for side effects. Five to seven medications addressing interconnected symptoms driven by initial pain medication.

The Comorbidity Accumulation Pattern

Initial injury complicated by pre-existing hypertension, diabetes, or anxiety. Each condition receives multiple medications. Injury recovery complicated by medication-induced adverse effects (hypertensive medication causing weight gain, diabetes medication causing hypoglycemia, anxiety medication causing sexual dysfunction), necessitating additional medications. Progressive polypharmacy cascade.

The Multi-Specialist Pattern

Claimant sees pain specialist (prescribes pain medications), psychiatrist (prescribes antidepressant and benzodiazepine), cardiologist (prescribes cardiovascular agents), GP (prescribes additional agents and manages comorbidities). Specialist medications accumulate without central coordination. No single prescriber sees full medication regimen. Polypharmacy results from fragmented prescribing.

Polypharmacy Risk Stratification

Deprescribing Strategies for Polypharmacy

Deprescribing Initiation

Deprescribing begins with medication review identifying: medications without clear current indication, duplicate therapy (two agents from same class), medications addressing adverse effects of other medications, and medications with inadequate efficacy justification. Typical polypharmacy reviews identify 20 to 40 percent of medications as candidates for deprescribing.

Deprescribing Sequencing

Deprescribing should follow logical sequence: first, remove medications addressing side effects of other medications (allowing dose reduction or cessation of causative agent). Second, deprescribe duplicate therapies, consolidating to single agents. Third, address medications with marginal indication or benefit. Avoid attempting deprescribing multiple agents simultaneously, which increases risk of symptom rebound and claimant non-compliance.

Monitoring Deprescribing Success

Successful deprescribing is demonstrated by: medication count reduction (goal typically 25 to 50 percent reduction from baseline), cost reduction (proportional to medication reduction), functional improvement (pain control maintenance or improvement, cognitive improvement, work participation increase), and sustained improvement at 6-month and 12-month follow-up.

Deprescribing failure indicators: symptom rebound necessitating medication re-introduction, claimant reluctance to continue deprescribing, functional decline, or new adverse events requiring additional medications. Failure typically indicates deprescribing was too rapid or addressed essential medication without adequate non-medication support.

Conclusion

Polypharmacy is a significant but preventable cost driver in insurance claims. Proactive medication review focused on identifying and deprescribing unnecessary medications can reduce annual claim costs by 15 to 30 percent while simultaneously improving functional outcomes and accelerating recovery. Insurance schemes should implement polypharmacy screening at claim registration and trigger medication review for all claimants on five or more chronic medications.